Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY.

Slides:

Advertisements

Similar presentations

0 HHS Influenza Vaccine Projects for NVAC Meeting June 7-8, 2005 By: Dr. Robin Robinson (HHS/OPHEP)

Advertisements

Vaccines and Related Biological Products

Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.

Vaccine Technology. Newer Technology for Dosing:

HHS Pandemic Influenza Vaccine Program VRBPAC Meeting Robin Robinson, Ph.D. Director, BARDA Deputy Assistant Secretary, ASPR November 14, 2012.

Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.

Vaccines1 Chapter 14 Also see on-line Influenza resource at nes.htm The Parents' Guide to Childhood Immunizations.

Pre-2003 Pandemic Influenza Vaccine Goal & Strategy

Vaccines Robert Beatty MCB150. Passive vs Active Immunity  Passive immunization transfer of antibodies  Vaccines are active immunizations (mimic natural.

WHO Draft Rapid Response + Containment, May 2006.

National Vaccine Advisory Committee June 7, 2005 Pandemic Influenza Vaccine Research and Development Linda C. Lambert Chief, Respiratory Diseases Branch.

National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.

0 HHS Influenza Vaccine Projects for NVAC Meeting November 29-30, 2005 By: Dr. Robin Robinson Sr. Project Officer ORDC/OPHEP/DHHS.

Influenza Vaccination

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Smallpox and Influenza "In early 1962 long queues attended any clinic in Birmingham offering vaccination, because three patients with smallpox were in.

Pandemic Influenza Preparedness Kentucky Department for Public Health Department for Public Health.

Preparing for Pandemic Influenza Anna Lönnroth European Commission DG Research: Health Research Priority Medicines for Europe and the World.

1 Pandemic Influenza Vaccine Development Pandemic Influenza Vaccine Development sanofi pasteur R&D, France Frederick R. Vogel, Ph.D.

Vaccines Polio - close to eradication. In 2001 >1000 cases worldwide; last wild case in Americas in Peru in 1991.

Dr Hannah Kibuuka Makerere University Walter Reed Project Presentation at the Uganda Medical Association-Uganda Veterinary Association joint conference.

Influenza Vaccine Development

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

Pandemic Influenza; A Harbinger of Things to Come Michael T Osterholm PhD, MPH Director, Center for Infectious Disease Research and Policy Associate Director,

Phagocyte. B cells Receptor B Cell Naïve B cell B cells and antibodies daughter cells produce antibodies phagocyte consumes an antibody coated virus.

Infection.... Our ViIlain.  There are three main types of Influenza Viruses. (many strains)  Type A  Type B  Type C – Not clinically important in.

Methods used to control the spread of infection 2.02 Understand infection control procedures.

17-1 Topics Principals of immunization Vaccines Immunizations.

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

Update on Pandemic Vaccine Development 3 rd WHO WPRO/SEARO NIC Meeting August, 2009, Beijing Masato Tashiro, MD., PhD. Director, WHO Collaborating.

Food and Drug Administration

WHAT DO YOU KNOW ABOUT VACCINES? Process in the body? Examples Invented by? Any worries? Interesting facts.

Avian Influenza When avian influenza hits will science have an efficient vaccine?

VACCINES: PRINCIPLES & PRACTICE. What is a vaccine? - an antigenic preparation used to produce active immunity to a disease, in order to prevent or ameliorate.

Effectiveness of Sub-capsular Meningococcal Vaccines An Approach to Evaluate Vaccines for the Prevention of Invasive Group B Meningococcal Disease VRBPAC.

1 Licensure of Pandemic Influenza Vaccines: Demonstration of Effectiveness Vaccines and Related Biological Products Advisory Committee Meeting February.

VRBPAC Topic #2: Clinical Development of Influenza Vaccines for Pre-pandemic Use Joseph G. Toerner, MD, MPH VCTB/DVRPA/OVRR/CBER/FDA February 27, 2007.

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Five: Immunology, Assay Standardization,

Influenza A (H1N1) Vaccine Vaccines and Related Biological Products Advisory Committee Meeting, 23 July 2009 Raburn Mallory, M.D. Proprietary Vaccines.

Pandemic Vaccines Current and Future Issues 30 January 2007 Beijing Keiji Fukuda Global Influenza Programme.

FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.

Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting September 27, 2006 Barbara L. Mulach, Ph.D. National Institute.

Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.

1 H5N1 Influenza Virus Vaccine, A/Vietnam/1203/2004 (Clade 1) VRBPAC Presentation Kenneth P. Guito, MBA Strategic Project Office.

Novartis Vaccines - Influenza A H1N1v vaccine development Theodore F Tsai MD MPH July 23, 2009 DHHS supported influenza cell culture vaccine production.

CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.

$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.

1 Vaccines and Related Biological Products Advisory Committee Meeting FluBlok ® : Influenza Vaccine, Recombinant Hemagglutinin Applicant: Protein Sciences.

Design of randomized, double-blind, controlled, multi-center phase IIb trials as part of the EU- funded UNISEC project to assess the safety, immunogenicity.

1 Considerations in the Pre- and Early Pandemic Use of Influenza Vaccine Jesse L. Goodman, MD, MPH Center for Biologics Evaluation and Research, VRBPAC,

HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV.

Pandemic Influenza Vaccine Manufacture Preparedness Lin Su Sinovac Biotech Co., Ltd.

Viral vaccines .

1 Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine After Priming With an.

Vaccine; To be effective  Must stimulate as many of the body's defence mechanisms as possible.  It is not necessary to get 100% uptake of vaccine in.

HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK

The more Effective FLU VACCINE PROBLEM

Zika virus vlp Creative Biostructure develops a safe, effective and straightforward strategy to rapidly produce a Zika vaccine. Our Zika Virus VLPs are.

Novel vaccine adjuvants for infectious diseases aninal

Vaccine development for pandemic influenza

Housekeeping May 1st 31 field trip, transport yourself to the Shady Lakes, pm. PCR results gel is posted (report) This lecture paper discussion.

Case presentation of non-clinical and clinical development of vaccines

Breadth of binding and HAI activity of serum Ab from i. n. + i. p

Reverse Vaccinology: Developing Vaccines in the Era of Genomics

Zika Virus: Immunity and Vaccine Development

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

Higher Human Biology Unit 3 – Neurobiology and Immunology

“Cost effectiveness analysis of school influenza vaccination program”

Cross-protection against variants within a subtype after intranasal immunization with vaccine from MDCK cell-adapted Vac-3 P22. Cross-protection against.

Presentation transcript:

Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY

Inactivated vaccine approach Proven technology - Used successfully in 1957 and Abundant efficacy data in both pandemic and interpandemic years - Very safe, with large safety database Manufacturing capacity exists in potentially large scale Licensing would be relatively straightforward

Inactivated vaccine approach Unlikely to induce mucosal immunity - May be less effective in preventing spread Protection may be strain specific - Little if any cellular immune response Requires multiple doses Manufacturing capacity limited by availability of eggs and capacity for expansion limited - Cell culture strategies might circumvent this problem

Recent clinical evaluations of potential pandemic viruses Duck Singapore/97 (H5N3) as a vaccine for Hong Kong/97 Recombinant, baculovirus-expressed HA of A/Hong Kong/156/97 (H5) Whole virion A/Singapore/1/57 (H2N2) and A/Hong Kong/1073/99 (H9N2) Whole virion and subunit A/Hong Kong/1073 (H9N2)

Egg-grown Duck/Singapore No adjuvant MF59 adjuvant ug HA 15 ug HA ug HA Study day Nicholson et al Lancet 357:1937, 2001

Egg-grown Duck/Singapore Duck Singapore Hong Kong ug HA 15 ug HA ug HA Study day Nicholson et al Lancet 357:1937, 2001

Reimmunization with Duck/Singapore MF59 Stephenson et al, Vaccine 21:1687, 2003 Base Day mo Day 21 Plain

Key issues [1] Development of standardized, validated surrogate markers of protection Responses to inactivated vaccines may be very strain specific - evaluation of strategies to broaden responses Adjuvants should be evaluated. Ratio of antigen to adjuvant may be important Pre-pandemic priming dose with heterologous variants should be explored Dose responses relationships may not be obvious

Recombinant rHA H5 Vaccine Insect cell expressing rHA RBCs Purified rHA H5 SDS-PAGE

Phase I evaluation of rH5 Randomized to interval between doses (21, 28, or 42 days) and then to dose groups (90 ug, 45 ug, 25 ug, 90/10 ug, placebo) - Total of 15 groups Vaccine or placebo administered in total of 1 mL by i.m. injection Sera before and 14 days after dose 1, and before and 7, 14, 21, and 28 days after dose 2